Dynavax Technologies Corporation

OUR COMPANY is a commercial-stage biopharmaceutical company that develops and sells innovative vaccines to protect against infectious diseases. The company focuses on maximizing the use of its HEPLISAV-B® hepatitis B vaccine, expanding its portfolio of vaccine candidates using its CpG 1018® adjuvant technology, and finding strategic growth opportunities through collaborations. HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] is the company's first marketed product. It is approved in the United States, the European Union, and the United Kingdom for preventing infection from all known subtypes of hepatitis B virus (HBV) in adults aged 18 years and older. HEPLISAV-B is the only two-dose hepatitis B vaccine for adults approved in these regions. In Phase 3 trials, it showed faster and higher protection rates with two doses in one month compared to other approved hepatitis B vaccines, which require three doses over six months, with similar safety profiles. The company received marketing authorization in February 2021 from the European Commission and in March 2023 in the United Kingdom. In May 2021, the company partnered with Bavarian Nordic for marketing and distribution of HEPLISAV-B in Germany, and commercial shipments began in Germany in May 2022. The company is also developing other product candidates using its CpG 1018 adjuvant. These include vaccine candidates for shingles and plague, and additional vaccine programs in preclinical development. The shingles vaccine program, Z-1018, is an investigational candidate for preventing shingles in adults aged 50 and older.